X4 Pharmaceuticals
Yahoo Finance • 10 days ago
X4 Pharmaceuticals to reduce 50% of workforce
* X4 Pharmaceuticals (NASDAQ:XFOR [https://seekingalpha.com/symbol/XFOR]) has announced a restructuring program to align resources with its long-term strategy to complete the Phase 3 4WARD trial for chronic neutropenia. * The plan incl... Full story
Yahoo Finance • 10 days ago
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M John Volpone appointed Chief Operating Officer, in addition to his current role as Presiden... Full story
Yahoo Finance • 19 days ago
Sitryx appoints Adam Mostafa as Chief Financial Officer
Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx T... Full story
Yahoo Finance • last month
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 12, 2025, the company issued... Full story
Yahoo Finance • last month
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement
BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today closed an upsized private placement of 11,040,776 shares of commo... Full story
Yahoo Finance • last month
X4 Pharmaceuticals secures $60 million in financing, appoints new leadership
BOSTON - X4 Pharmaceuticals (NASDAQ:XFOR) has secured approximately $60 million in a private placement financing led by Coastlands Capital, with participation from Bain Capital Life Sciences, New Enterprise Associates, and other investors,... Full story
- T
Mentioned:
Yahoo Finance • last month
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as President and David Ki... Full story
Yahoo Finance • 3 months ago
X4 Pharmaceuticals presents positive data from neutropenia trial
BOSTON - X4 Pharmaceuticals (NASDAQ:XFOR), a clinical-stage biotech company currently trading near its 52-week low of $2.82 (down from $31.20), presented positive results from its completed Phase 2 trial of mavorixafor in the treatment of... Full story
Yahoo Finance • 6 months ago
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026 4WARD trial protocol refined, increasing confidence in successful ou... Full story
Yahoo Finance • 7 months ago
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth q... Full story
Yahoo Finance • 7 months ago
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
BOSTON and DUBAI, United Arab Emirates, Feb. 19, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, and taiba rare, a taiba Healthcare comp... Full story
Yahoo Finance • 8 months ago
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropenia on track for mid-2025 Right-sizing commercial efforts to optimize XOLREMDI promotion and support U.S. WHIM syndrome community Restructuring impact... Full story
Yahoo Finance • 8 months ago
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025, the company issued... Full story
Yahoo Finance • 8 months ago
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome granted in 2024 Decision on MAA expected in 1H 2026 BOSTON, Jan. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuti... Full story
Yahoo Finance • 2 years ago
X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences
BOSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in fireside chats... Full story
Yahoo Finance • 2 years ago
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
U.S. New Drug Application for mavorixafor in WHIM syndrome accepted for Priority Review, establishing a PDUFA target action date of April 30, 2024; X4 eligible to receive Priority Review Voucher if approved Presentations of additional dat... Full story
Yahoo Finance • 2 years ago
X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023
BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for t... Full story
Yahoo Finance • 2 years ago
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on October 31, 2023, the company issued... Full story
Yahoo Finance • 2 years ago
X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the appointment of R. Keith Woods as an independent dir... Full story
